Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-10-31 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司关于持股5%以上股东股份减持计划时间届满暨减持结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the expiration of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's initial holdings, the planned reduction, the actual reduction executed, and confirms the completion of the reduction plan. The document does not contain financial statements or detailed financial performance data but is a regulatory announcement about shareholding changes by a major shareholder. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full report or earnings release.
2022-10-31 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司部分募投项目增加实施主体、实施地点暨使用部分募集资金向全资子公司实缴出资以实施募投项目的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding changes in the implementation subject and location of certain fundraising projects of Kemei Diagnostics Technology Co., Ltd., as well as the use of part of the raised funds to pay-in capital to a wholly-owned subsidiary. It references regulatory approvals, fundraising amounts, adjustments to investment projects, and internal approvals by the board and supervisory committee. The document is not a full annual or interim report, nor is it a simple announcement or certification. It is a formal audit or verification opinion related to the use of raised funds and compliance with regulatory requirements. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory checks related to financial or fundraising activities, excluding full annual reports. The document length (5086 characters) and content support this classification with high confidence. Q4 2022
2022-10-28 Chinese
科美诊断技术股份有限公司关于部分募投项目增加实施主体、实施地点暨使用部分募集资金向全资子公司实缴出资以实施募投项目的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of 科美诊断技术股份有限公司 regarding changes in the implementation details of certain fundraising projects and the use of part of the raised funds to increase capital in a wholly-owned subsidiary. It includes detailed information about the fundraising, adjustments in project investment amounts, changes in project implementation entities and locations, and the use of funds. The document also contains opinions from independent directors, the supervisory board, and the sponsoring institution, confirming the legitimacy and compliance of the decisions. The content focuses on the management and use of raised capital and related corporate governance matters, without presenting full financial statements or quarterly results. It is not a full annual or interim report, nor an earnings release or audit report. It is a regulatory announcement about capital use and project implementation changes approved by the board, which fits best under Capital/Financing Update (CAP). The document length (4848 characters) is sufficient to be a substantive announcement rather than a brief notice or report publication announcement.
2022-10-28 Chinese
科美诊断技术股份有限公司第二届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of the company 科美诊断技术股份有限公司 regarding the approval of the company's 2022 third quarter report and other related resolutions. It includes details about the meeting date, attendance, voting results, and legal compliance statements. The document explicitly states that the supervisory board has reviewed and approved the 2022 third quarter report, but the full report is published separately on the Shanghai Stock Exchange website. The document itself does not contain the financial statements or substantive financial data of the quarterly report but is an announcement of the supervisory board's approval and related decisions. Given the document length (1243 characters) and content, it fits the category of a Regulatory Filing (RNS) rather than the actual Interim/Quarterly Report (IR).
2022-10-28 Chinese
科美诊断技术股份有限公司独立董事关于第二届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a board meeting held on October 28, 2022. It discusses approval of a proposal related to changes in the implementation of certain fundraising projects and the use of raised funds. The document references compliance with company law, stock exchange listing rules, and internal company regulations. It is not a full financial report, earnings release, or regulatory filing but rather a formal opinion related to board matters and fundraising project implementation. Given the content focuses on board meeting matters and independent directors' opinions, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a voting result announcement or proxy solicitation. Therefore, the classification is MANG with high confidence.
2022-10-28 Chinese
科美诊断技术股份有限公司2022年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2022 Third Quarter Report" of 科美诊断技术股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data for the quarter, including revenue, net profit, earnings per share, cash flow, and shareholder information. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification, and the document length and content support it being the actual report rather than a notice or summary. 9M 2022
2022-10-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.